Compare GDDY & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDDY | BBIO |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 15.3B |
| IPO Year | 2014 | 2019 |
| Metric | GDDY | BBIO |
|---|---|---|
| Price | $80.98 | $68.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 24 |
| Target Price | ★ $145.06 | $83.00 |
| AVG Volume (30 Days) | 2.4M | ★ 2.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 6.22 | N/A |
| Revenue | N/A | ★ $502,076,000.00 |
| Revenue This Year | $8.02 | $88.86 |
| Revenue Next Year | $6.08 | $74.11 |
| P/E Ratio | $13.91 | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $73.06 | $28.33 |
| 52 Week High | $193.55 | $84.94 |
| Indicator | GDDY | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 34.97 | 47.47 |
| Support Level | $73.06 | $61.95 |
| Resistance Level | $93.00 | $68.71 |
| Average True Range (ATR) | 4.35 | 3.33 |
| MACD | 0.38 | 0.54 |
| Stochastic Oscillator | 38.29 | 44.46 |
GoDaddy Inc provides digital solutions and services for entrepreneurs, small businesses, individuals, organizations, developers, designers, and domain investors. It offers tools intended to support business creation and management through an integrated service platform. The company operates through two segments: Applications and Commerce (A&C) and Core Platform (Core). The majority of the company's revenue is derived from the Core Platform segment, which consists of sales of domain registrations and renewals, aftermarket domain sales, website hosting products and website security products. Geographically, it generates the maximum revenue from the United States.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.